MX364946B - Sistema adyuvante mejorado para la administración de vacunas orales. - Google Patents
Sistema adyuvante mejorado para la administración de vacunas orales.Info
- Publication number
- MX364946B MX364946B MX2014011806A MX2014011806A MX364946B MX 364946 B MX364946 B MX 364946B MX 2014011806 A MX2014011806 A MX 2014011806A MX 2014011806 A MX2014011806 A MX 2014011806A MX 364946 B MX364946 B MX 364946B
- Authority
- MX
- Mexico
- Prior art keywords
- adminstration
- adjuvant system
- oral vaccine
- improved adjuvant
- compositions
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 229940126578 oral vaccine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261686372P | 2012-04-04 | 2012-04-04 | |
| PCT/US2013/000102 WO2013151595A1 (en) | 2012-04-04 | 2013-04-03 | Improved adjuvant system for oral vaccine adminstration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011806A MX2014011806A (es) | 2015-06-03 |
| MX364946B true MX364946B (es) | 2019-05-15 |
Family
ID=49300897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011806A MX364946B (es) | 2012-04-04 | 2013-04-03 | Sistema adyuvante mejorado para la administración de vacunas orales. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20150079130A1 (enExample) |
| EP (2) | EP3549605A1 (enExample) |
| JP (1) | JP6240155B2 (enExample) |
| KR (1) | KR101867428B1 (enExample) |
| AU (1) | AU2013243971B2 (enExample) |
| CA (1) | CA2903313C (enExample) |
| DK (1) | DK2833914T3 (enExample) |
| IL (1) | IL234937B (enExample) |
| MX (1) | MX364946B (enExample) |
| WO (1) | WO2013151595A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3107568B1 (en) * | 2014-02-20 | 2024-03-27 | Vaxart, Inc. | Formulations for small intestinal delivery |
| WO2015192216A1 (en) * | 2014-06-20 | 2015-12-23 | University Of Saskatchewan | Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis |
| KR102678401B1 (ko) | 2015-06-12 | 2024-06-26 | 박사르트, 인크. | Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들 |
| CA3016860A1 (en) * | 2016-03-07 | 2017-09-14 | Glaxosmithkline Biologicals Sa | Drug delivery particles |
| CA3097058A1 (en) * | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Additives for protein formulations to improve thermal stability |
| KR102369740B1 (ko) | 2020-09-21 | 2022-03-02 | 부경대학교 산학협력단 | 자궁경부암 조기진단을 위한 모바일 질확대경 장치 |
| WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
| CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4133397A (en) * | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
| WO1998035562A1 (en) * | 1997-02-14 | 1998-08-20 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| US20030162955A1 (en) * | 1998-03-17 | 2003-08-28 | Lionel Chalus | Isolated mammalian membrane protein genes; related reagents |
| ES2260916T3 (es) * | 1998-07-08 | 2006-11-01 | Kirin-Amgen, Inc. | Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica. |
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| WO2004018698A2 (en) * | 2002-08-20 | 2004-03-04 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| WO2004073652A2 (en) * | 2003-02-20 | 2004-09-02 | Becton Dickinson And Company | Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| WO2008039432A1 (en) * | 2006-09-26 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
| EP2464341B1 (en) * | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB0919690D0 (en) * | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
-
2013
- 2013-04-03 MX MX2014011806A patent/MX364946B/es active IP Right Grant
- 2013-04-03 AU AU2013243971A patent/AU2013243971B2/en not_active Ceased
- 2013-04-03 CA CA2903313A patent/CA2903313C/en active Active
- 2013-04-03 WO PCT/US2013/000102 patent/WO2013151595A1/en not_active Ceased
- 2013-04-03 JP JP2015504545A patent/JP6240155B2/ja not_active Expired - Fee Related
- 2013-04-03 KR KR1020147030919A patent/KR101867428B1/ko not_active Expired - Fee Related
- 2013-04-03 EP EP19151134.4A patent/EP3549605A1/en not_active Withdrawn
- 2013-04-03 US US13/261,964 patent/US20150079130A1/en not_active Abandoned
- 2013-04-03 DK DK13772028.0T patent/DK2833914T3/en active
- 2013-04-03 EP EP13772028.0A patent/EP2833914B1/en active Active
-
2014
- 2014-10-02 IL IL234937A patent/IL234937B/en unknown
-
2018
- 2018-12-06 US US16/212,088 patent/US20190105389A1/en not_active Abandoned
-
2020
- 2020-11-05 US US17/090,292 patent/US20210052725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013243971B2 (en) | 2017-01-05 |
| IL234937B (en) | 2021-10-31 |
| JP6240155B2 (ja) | 2017-11-29 |
| US20190105389A1 (en) | 2019-04-11 |
| CA2903313A1 (en) | 2013-10-10 |
| EP2833914A4 (en) | 2016-03-30 |
| MX2014011806A (es) | 2015-06-03 |
| IL234937A0 (en) | 2014-12-31 |
| US20210052725A1 (en) | 2021-02-25 |
| EP2833914A1 (en) | 2015-02-11 |
| CA2903313C (en) | 2019-10-22 |
| WO2013151595A1 (en) | 2013-10-10 |
| EP2833914B1 (en) | 2019-01-16 |
| US20150079130A1 (en) | 2015-03-19 |
| KR20150002755A (ko) | 2015-01-07 |
| AU2013243971A1 (en) | 2014-10-02 |
| JP2015512441A (ja) | 2015-04-27 |
| EP3549605A1 (en) | 2019-10-09 |
| KR101867428B1 (ko) | 2018-07-19 |
| DK2833914T3 (en) | 2019-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2018002301A (es) | Composiciones de glucano y usos de las mismas. | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| BR112012029912A2 (pt) | vácinas de combinação de nanotransportadores sintéticos | |
| PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IN2013MU03583A (enExample) | ||
| PH12014501991B1 (en) | Phenicol antibacterials | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MX2015011109A (es) | Composiciones estables de activador de glucoquinasa. | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| IN2013MU01177A (enExample) | ||
| MX2021003908A (es) | Polipeptidos de accion prolongada y metodos para su produccion y administracion. | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| IN2013MU03422A (enExample) | ||
| IN2013MU03309A (enExample) | ||
| IN2013CH04314A (enExample) | ||
| IN2013MU03428A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |